United Therapeutics CORP 10-Q quarterly reports

United Therapeutics reports mixed financial results for Q2 2026, with Tyvaso DPI sales up, but overall revenues down due to Nebulized Tyvaso decline, while advancing key pipeline drugs and facing ongoing litigation.

United Therapeutics reports a decrease in net income for Q1 2026 compared to the prior year, driven by increased operating expenses and strategic investments, while advancing key pipeline programs.

United Therapeutics reports robust Q3 2025 revenue growth driven by Tyvaso DPI sales and significant progress in its organ manufacturing and xenotransplantation programs.

United Therapeutics Corporation announced robust second-quarter financial results, fueled by significant growth in Tyvaso DPI sales, while making substantial progress in its innovative organ manufacturing and xenotransplantation programs.

United Therapeutics' Q1 2025 revenue increased by 17% year-over-year, driven by growth in Tyvaso DPI sales and pipeline advancements in IPF and PPF treatments.

United Therapeutics' Q3 2024 results show significant revenue growth, primarily driven by increased sales of Tyvaso DPI and overall expansion in the number of patients using their therapies.

United Therapeutics reports a strong second quarter with revenue growth driven by Tyvaso DPI and advancements in organ manufacturing programs.

United Therapeutics Corporation reported a significant increase in revenue and net income for the first quarter of 2024, primarily driven by the strong performance of Tyvaso DPI.